| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8214210 | International Journal of Radiation Oncology*Biology*Physics | 2016 | 24 Pages |
Abstract
Sulfasalazine does not reduce enteritis during pelvic RT and may be associated with a higher risk of adverse events than placebo. This trial illustrates the importance of confirmatory phase 3 trials in the evaluation of symptom-control agents.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Robert C. MD, Daniel G. MD, Jeff A. PhD, Heshan MS, James A. MD, James D. MD, Ronald MD, Grant R. MD, Rex B. MD, Ben MD, Matthew J. RN, CNP, Charles L. MD, Alliance for Clinical Trials in Oncology Alliance for Clinical Trials in Oncology,